BioImagene

company

About

BioImagene offers tissue-based integrated hardware and software solutions for clinical diagnostics and drug discovery applications.

  • 51 - 100

Details

Last Funding Type
Series D
Last Funding Money Raised
$26M
Industries
Biotechnology,Health Care,Health Diagnostics
Founded date
Jan 1, 2003
Number Of Employee
51 - 100
Operating Status
Active

BioImagene, Inc. provides digital pathology solutions for clinical diagnostics and drug discovery applications. It develops and distributes integrated hardware and software systems to acquire, view, share, manage, archive, and analyze tissue images in pathology laboratories. The company offers IHC algorithms, such as HER2, ER/PR, and p53 for breast cancer; Ki67 for breast, brain, and prostate cancers; CD138 for multiple myeloma; CD3/CD20 for lymphoma; iSlide input device, a device that allows pathologists to use a microscope interface to manipulate digital images of slides; and iScan Coreo Au digital slide scanners that enable digital pathology applications, such as image analysis, telepathology, remote microscopy, and education. It serves cancer research laboratories, academic medical centers, community hospitals, reference laboratories, teaching hospitals, biotech companies, and pharmaceutical companies. BioImagene, Inc. was founded in 2003 and is based in Sunnyvale, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$30.20M
BioImagene has raised a total of $30.20M in funding over 2 rounds. Their latest funding was raised on Aug 19, 2008 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 19, 2008 Series D $26M 1 Detail
Oct 12, 2004 Series B $4.20M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
BioImagene is funded by 2 investors. National Healthcare Services and Authosis Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
National Healthcare Services Series D
Authosis Ventures Series B